Merck & Co. is in talks to buy Seagen, a biotech company that develops drugs to treat cancer, sources told the Wall Street Journal. Merck & Co. could pay about $40 billion, or more than $200 per Seagen share. The companies plan to close the deal before Merck announces its Q2 2022 financial results, due July 28.